These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31949258)

  • 1. Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions.
    Xiong C; Wen Y; Zhao J; Yin D; Xu L; Chelariu-Raicu A; Yao C; Leng X; Liu J; Chaudhari RR; Zhang S; Sood AK; Li C
    Sci Rep; 2020 Jan; 10(1):520. PubMed ID: 31949258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A synthetic bivalent peptide ligand of EphB4 with potent agonistic activity.
    Fan T; Liang B; Nie L; Wang J; Zhang H; Ciechanover A; Xu Y; An J; Huang Z
    Eur J Med Chem; 2022 Dec; 244():114804. PubMed ID: 36208510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
    Noren NK; Lu M; Freeman AL; Koolpe M; Pasquale EB
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5583-8. PubMed ID: 15067119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.
    Rutkowski R; Mertens-Walker I; Lisle JE; Herington AC; Stephenson SA
    Int J Cancer; 2012 Sep; 131(5):E614-24. PubMed ID: 22161689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity.
    Noberini R; Mitra S; Salvucci O; Valencia F; Duggineni S; Prigozhina N; Wei K; Tosato G; Huang Z; Pasquale EB
    PLoS One; 2011; 6(12):e28611. PubMed ID: 22194865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic interference with EphrinB2 signalling inhibits oxygen-induced angioproliferative retinopathy.
    Ehlken C; Martin G; Lange C; Gogaki EG; Fiedler U; Schaffner F; Hansen LL; Augustin HG; Agostini HT
    Acta Ophthalmol; 2011 Feb; 89(1):82-90. PubMed ID: 19764912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth.
    Kertesz N; Krasnoperov V; Reddy R; Leshanski L; Kumar SR; Zozulya S; Gill PS
    Blood; 2006 Mar; 107(6):2330-8. PubMed ID: 16322467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand-Dependent and Ligand-Independent Effects of Ephrin-B2-EphB4 Signaling in Melanoma Metastatic Spine Disease.
    Piffko A; Broggini T; Harms C; Adams RH; Vajkoczy P; Czabanka M
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of EphB4-Ephrin-B2 Signaling Reprograms the Tumor Immune Microenvironment in Head and Neck Cancers.
    Bhatia S; Oweida A; Lennon S; Darragh LB; Milner D; Phan AV; Mueller AC; Van Court B; Raben D; Serkova NJ; Wang XJ; Jimeno A; Clambey ET; Pasquale EB; Karam SD
    Cancer Res; 2019 May; 79(10):2722-2735. PubMed ID: 30894369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis.
    Sasine JP; Kozlova NY; Valicente L; Dukov J; Tran DH; Himburg HA; Kumar S; Khorsandi S; Chan A; Grohe S; Li M; Kan J; Sehl ME; Schiller GJ; Reinhardt B; Singh BK; Ho R; Yue P; Pasquale EB; Chute JP
    Cancer Res; 2024 Mar; 84(6):919-934. PubMed ID: 38231476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-dependent EphB4 activation serves as an anchoring signal in glioma cells.
    Kawahara Y; Furuta T; Sabit H; Tamai S; Dong Y; Jiapaer S; Zhang J; Zhang G; Oishi M; Miyashita K; Hayashi Y; Nakada M
    Cancer Lett; 2019 May; 449():56-65. PubMed ID: 30776480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor.
    Noren NK; Yang NY; Silldorff M; Mutyala R; Pasquale EB
    Biochem J; 2009 Aug; 422(3):433-42. PubMed ID: 19552627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential protein expression and oncogenic gene network link tyrosine kinase ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers.
    Liersch-Löhn B; Slavova N; Buhr HJ; Bennani-Baiti IM
    Int J Cancer; 2016 Mar; 138(5):1220-31. PubMed ID: 26414866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ephrin‑B2 inhibits cell proliferation and motility in vitro and predicts longer metastasis‑free survival in breast cancer.
    Magic Z; Sandström J; Perez-Tenorio G
    Int J Oncol; 2019 Dec; 55(6):1275-1286. PubMed ID: 31638179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ephrin-B2 reverse signaling is required for axon pathfinding and cardiac valve formation but not early vascular development.
    Cowan CA; Yokoyama N; Saxena A; Chumley MJ; Silvany RE; Baker LA; Srivastava D; Henkemeyer M
    Dev Biol; 2004 Jul; 271(2):263-71. PubMed ID: 15223333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma.
    Randolph ME; Cleary MM; Bajwa Z; Svalina MN; Young MC; Mansoor A; Kaur P; Bult CJ; Goros MW; Michalek JE; Xiang S; Keck J; Krasnoperov V; Gill P; Keller C
    PLoS One; 2017; 12(8):e0183161. PubMed ID: 28817624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination.
    Lennon S; Oweida A; Milner D; Phan AV; Bhatia S; Van Court B; Darragh L; Mueller AC; Raben D; Martínez-Torrecuadrada JL; Pitts TM; Somerset H; Jordan KR; Hansen KC; Williams J; Messersmith WA; Schulick RD; Owens P; Goodman KA; Karam SD
    Clin Cancer Res; 2019 Jun; 25(11):3352-3365. PubMed ID: 30944125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic changes occur in patterns of endometrial EFNB2/EPHB4 expression during the period of spiral arterial modification in mice.
    Zhang J; Dong H; Wang B; Zhu S; Croy BA
    Biol Reprod; 2008 Sep; 79(3):450-8. PubMed ID: 18463357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers.
    Bhatia S; Sharma J; Bukkapatnam S; Oweida A; Lennon S; Phan A; Milner D; Uyanga N; Jimeno A; Raben D; Somerset H; Heasley L; Karam SD
    Clin Cancer Res; 2018 Sep; 24(18):4539-4550. PubMed ID: 29848571
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.